The effect of prinomastat (AG3340), a potent inhibitor of matrix metalloproteinases, on a subacute model of proliferative vitreoretinopathy

Current Eye Research

Volumn 20, Issue 6, 2000, Pages 447-453

  Ozerdem, U ^a   Mach Hofacre, B ^a   Cheng, L ^a   Chaidhawangul, S ^a   Keefe, K ^a   McDermott, C D ^a   Bergeron Lynn, G ^a   Appelt, K ^a   Freeman, W R ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Matrix metalloproteinase inhibitors; Proliferative vitreoretinopathy; Treatment

Indexed keywords

DISPASE; DRUG VEHICLE; MATRIX METALLOPROTEINASE INHIBITOR; PRINOMASTAT; UNCLASSIFIED DRUG; WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG STRUCTURE; HISTOPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; RABBIT; RANDOMIZATION; RETINA DETACHMENT; SCORING SYSTEM; VITREORETINOPATHY; VITREOUS BODY;

EID: 0033828802     PISSN: 02713683     EISSN: None     Source Type: Journal    
DOI: 10.1076/0271-3683(200006)2061-YFT447     Document Type: Article

References (35)

1. The pathophysiology of proliferative vitreoretinopathy in its management
2. Proliferative vitreoretinopathy
3. Proliferative vitreoretinopathy: A personal account of its pathogenesis and treatment
4. Inhibition of experimental proliferative vitreoretinopathy in rabbits by suramin
5. Effects of cytotoxic drugs on proliferative vitreoretinopathy in the rabbit cell injection model
6. The effect of triamcinolone acetonide on a refined experimental model of proliferative vitreoretinopathy
7. Daunorubicin treatment in a refined experimental model of proliferative vitreoretinopathy
8. An intravitreal sustained-release triamcinolone and 5-fluorouracil codrug in the treatment of experimental proliferative vitreoretinopathy
9. Does the presence of heparin and dexamethasone in the vitrectomy infusate reduce reproliferation in proliferative vitreoretinopathy?
10. Aclacinomycin A in the treatment of experimental proliferative vitreoretinopathy. Efficacy and toxicity in the rabbit eye
11. Antiproliferative effect of retinoic acid in intravitreous silicone oil in an animal model of proliferative vitreoretinopathy
12. Silicone oil as a delivery vehicle for BCNU in rabbit proliferative vitreoretinopathy
13. Inhibition of matrix metalloprotenases inhibits anterior segment fibroblast mediated collagen contraction
14. A prospective study of matrix metalloproteinases in proliferative vitreoretinopathy
15. A new model of proliferative vitreoretinopathy
16. Intraocular properties of AG3340,a selective matrix metalloproteinases inhibitor with antiangiogenic activity
17. A comparison of different cellular inocula in an experimental model of massive periretinal proliferation
18. Matrix metalloproteinases and metalloproteinase inhibitors in human interphoto-receptor matrix and vitreous
19. Matrix metalloproteinases and their inhibitors in human vitreous
20. New discoveries on the roles of matrixmetalloproteinases in ocular cell biology and pathology
21. Matrix metalloproteinases and metalloproteinase inhibitors in choroidal neovascular membranes
22. The vascular component of proliferative vitreoretinopathy membranes
23. Rodent pharmacokinetics and anti-tumor efficacy studies with a series of synthethic inhibitors of matrix metalloproteinases
24. Pharmacokinetics and efficacy of a novel matrix metalloproteinase inhibitor, AG3340, in single agent and combination therapy against B16-F10 melanoma tumors developing after IV-tail implantation in C57BL/6 mice
25. Marked inhibition of the proliferation of human adenocarcinoma colon tumors in vivo by orally-administered AG3340, a novel matrix metalloproteinase inhibitor
26. Marked inhibition of tumor growth in a malignant glioma tumor model by the novel synthetic matrix metalloprotease inhibitor, AG3340
27. Ocular bioavailability and pharmacokinetics of AG3340, a potent MMP inhibitor with antiangiogenic activity, following oral administration
28. Phase I study of the matrix metalloprotease inhibitor AG3340 given in a single doses to healthy volunteers
29. Evaluation of long-term effects of intraocular injections of AG3340, a selective matrix metalloprotease inhibitor
30. The role of matrix metalloproteinases (MMPS) in human retinal pigment epithelial-induced collagen matrix contraction and adhesion to collagen type-I
31. Matrix and the retinal pigment epithelium in proliferative retinal disease
32. Efficacy of AG3340 a selective inhibitor of matrix metalloproteinases in an animal model of retinal neovascularization
33. Proliferative vitreoretinopathy. The mechanism of development of vitreoretinal traction
34. Traction retinal detachment